A genome-wide association study reveals 2 new susceptibility loci for atopic dermatitis - 04/09/15
Doi : 10.1016/j.jaci.2015.01.047
Heidi Schaarschmidt, ME a, ∗, David Ellinghaus, PhD a, ∗, Elke Rodríguez, PhD b, Anja Kretschmer, PhD b, c, Hansjörg Baurecht, MSc b, Simone Lipinski, PhD a, Ulf Meyer-Hoffert, MD, PhD b, Jürgen Harder, PhD b, Wolfgang Lieb, MD d, Natalija Novak, MD e, Regina Fölster-Holst, MD b, Jorge Esparza-Gordillo, PhD f, g, Ingo Marenholz, PhD f, g, Franz Ruschendorf, PhD f, Norbert Hubner, PhD f, Eva Reischl, PhD c, Melanie Waldenberger, PhD c, Christian Gieger, PhD c, Thomas Illig, PhD h, Michael Kabesch, MD i, Xue-Jun Zhang, MD j, Feng-Li Xiao, PhD j, Young-Ae Lee, MD f, g, ∗, Andre Franke, PhD a, ∗, Stephan Weidinger, MD b, ∗ 
a Institute of Clinical Molecular Biology, Christian-Albrechts-Universität of Kiel, Kiel, Germany
d Institute of Epidemiology and Biobank PopGen, Christian-Albrechts-Universität of Kiel, Kiel, Germany
b Department of Dermatology, Venereology and Allergology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
c Research Unit of Molecular Epidemiology and Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
e Department of Dermatology and Allergy, University of Bonn, Bonn, Germany
f Max-Delbrück-Centrum (MDC) for Molecular Medicine, Berlin-Buch, Germany
g Pediatric Allergy, Experimental and Clinical Research Center, Universitätsmedizin Berlin, Berlin, Germany
h Hannover Unified Biobank, Hannover Medical School, Hannover, Germany
i Department of Pediatric Pneumology and Allergy, KUNO University Children's Hospital Regensburg, Regensburg, Germany
j Institute of Dermatology at No. 1 Hospital, Anhui Medical University, Hefei, China
| The project received infrastructure support through the DFG Cluster of Excellence “Inflammation at Interfaces” (grants EXC306 and EXC306/2) and was supported by the German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept (sysINFLAME, grant no. 01ZX1306A) and the PopGen 2.0 network (01EY1103). The KORA research platform was initiated and financed by the Helmholtz Center Munich, German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. |
|
| Disclosure of potential conflict of interest: N. Novak has received research support from the Germany Research Council (SFB704) and ALK-Abelló, has received consultancy fees from Leti Pharma and HAL Allergy, and has received lecture fees from Novartis, GlaxoSmithKline, MSD, ALK-Abelló, Bencard Allergy Therapeutics, HAL Allergy, and Stallergenes. M. Kabesch has received research support from the European Union (KBBE-2007-2-2-06, LSH-2004-1.2.5-1), the German Ministry of Education and Research (01ZX1306E, 01GS0810), and the German Research Foundation (SFB587B16) and has received lecture fees from European Respiratory Society, the European Academy of Allergy and Clinical Immunology, the American Thoracic Society, Novartis, and GlaxoSmithKline. S. Weidinger has received research support from NGFN (01GS0809, 01GS1818), Novartis, Pfizer, and Biogen Idec; is a board member for Novartis, Astellas, and Nutricia; has received consultancy fees from Novartis, Astellas, Pfizer, and Galderma; and has received lecture fees from Novartis, Pfizer, Pierre-Fabre, and Roche-Posay. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2015
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 136 - N° 3
P. 802-806 - septembre 2015 Retour au numéro
Article précédent
- A novel, nonanaphylactogenic, bispecific IgE-CD3 antibody eliminates IgE+ B cells
- Oktay Kirak, Gert Riethmüller
- Reduction in allergen-specific IgE binding as measured by microarray: A possible surrogate marker for effects of specific immunotherapy
- Eva Wollmann, Christian Lupinek, Michael Kundi, Regina Selb, Verena Niederberger, Rudolf Valenta
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?